1. Home
  2. NVAX vs EVO Comparison

NVAX vs EVO Comparison

Compare NVAX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Novavax Inc.

NVAX

Novavax Inc.

N/A

Current Price

$6.56

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

N/A

Current Price

$2.95

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVAX
EVO
Founded
1987
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
NVAX
EVO
Price
$6.56
$2.95
Analyst Decision
Hold
Strong Buy
Analyst Count
9
1
Target Price
$10.78
$7.00
AVG Volume (30 Days)
3.3M
115.9K
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.07
N/A
Revenue
$1,064,651,000.00
$887,396,457.00
Revenue This Year
$58.91
N/A
Revenue Next Year
N/A
$8.80
P/E Ratio
$3.16
N/A
Revenue Growth
20.27
N/A
52 Week Low
$5.01
$2.84
52 Week High
$11.55
$5.10

Technical Indicators

Market Signals
Indicator
NVAX
EVO
Relative Strength Index (RSI) 39.06 39.51
Support Level $6.36 $2.94
Resistance Level $6.84 $3.09
Average True Range (ATR) 0.22 0.09
MACD 0.04 0.01
Stochastic Oscillator 30.04 19.39

Price Performance

Historical Comparison
NVAX
EVO

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: